ReviewCancer metastasis reviews2025
Clinical subtypes of stage IV pancreatic ductal adenocarcinoma: a new perspective of clinical practices.
Review in Cancer metastasis reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies and becomes an increasing burden on our society, with nearly half of patients presenting with metastasis at diagnosis and a mortality rate that continues to rise during the past decade. Despite significant advances in understanding the molecular heterogeneity of PDAC, current classifications have yet to translate into clinical practice. In this review, we propose a novel clinical classification for stage IV PDAC based on distinct patterns of metastatic dissemination and highlight the ongoing efforts to tailor specific regimens for specific clinical subtypes. We further explore the underlying molecular mechanisms that may drive site-specific metastasis. We suggest that the new clinical subtypes could improve patient stratification, optimize clinical trial design, and ultimately enhance therapeutic outcomes in stage IV PDAC patients.
Indexed as
Identifiers
41117977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.